{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Tumor tissues from archived tissue specimens and/or a de novo biopsy were analyzed for ALK kinase domain mutations. Number of participants with one or more ALK mutations is presented.","groups":[{"description":"This reporting arm includes all Phase 1 participants who had documented ALK rearrangement.","id":"OG000","title":"ALK Positive Population (Phase 1)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Tumor Tissue analysis set included all participants of the ITT analysis set who had at least 1 molecular tumor biomarker assayed from either the screening archival or screening de novo tumor biopsy sample (or both).","reportingStatus":"POSTED","timeFrame":"Screening (up to 28 days)","title":"Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 1)","type":"SECONDARY","unitOfMeasure":"Participants"}